Azịza ngwa ngwa
Animal models mispredict human biology often enough that the regulatory ground has shifted: a 2024 systematic analysis in PLoS Biology found that only 5% of an…
Ihe Na-eme Model Preclinical dabara adabara mmadụ
Onye nrụpụta n'ogbe Peptides Zụrụ Peptides Ihe nlere anya nke dabara na mmadụ bụ nke amụma amụma ya dabere na sel mmadụ, ihe owuwu nke anụ ahụ mmadụ na physiology mmadụ karịa na extrapolation nke ụdị obe. Nkọwa FDA n'onwe ya maka usoro ụzọ ọhụrụ kpuchiri "Ụzọ nnwale ọhụrụ na atụmatụ eji enyocha nchekwa, arụmọrụ, na àgwà nke ọgwụ ọjọọ, bayoloji, na ngwaahịa FDA ndị ọzọ na-achịkwa,” n'ụzọ doro anya gụnyere sistemụ mmadụ dabere na vitro yana n'ụdị silico (FDA, Usoro nso nso a, ugbu a 2026). Nkọwa ahụ dị warara karịa okwu iwu ọ na-enwekarị mgbagwoju anya: FDA Modernization Act 2.0 dochie “ule preclinical (gụnyere ule na ụmụ anụmanụ)” na “ule na-abụghị nke ụlọ ọgwụ," na nkọwa iwu ọhụrụ nke ule na-abụghị nke ụlọ ọgwụ gụnyere n'ụzọ doro anya" ule na-abụghị mmadụ na vivo" ma depụta ule anụmanụ n'ime ụzọ ndị a ga-esi tinye " (Nyocha amụma FDA, 2026). NAM na ule na-abụghị nke ụlọ ọgwụ abụghị otu ihe, na Iwu wepụrụ ihe achọrọ na-amachibidoghị ọmụmụ anụmanụ.
Mkpa bụkwa ihe onwunwe nke ije, ọ bụghị naanị site na cell. A 2025 Ụzọ ntụgharị akụkụ akụkụ-na-chip na-akọwa usoro ndị a dị ka njikọ nke "akụkụ" (cellular architecture na physiological ọrụ) na "chip" (microfabricated ikpo okwu), ma jide na mkpa physiological chọrọ nhazi multiscale, Mmekọrịta anụ ahụ na anụ ahụ gụnyere vaskụla endothelium na-egosi na parenchymal na ngalaba njikọ., na ihe nrụtụ aka dị ka mmiri ike shiee, esemokwu na mkpakọ (Akụkụ-na-a-chip: Ụzọ maka nyocha ntụgharị asụsụ, 2025).
Nsonaazụ bara uru maka nkọwapụta reagent bụ na ihe nlereanya nwere ike ịbụ mmadụ n'ime sel ya ma ọ kaghị adị mkpa mmadụ na ịgụpụta ya.. A 2026 nyochaa nke reproducible organoid n'ichepụta aha extracellular matriks mgbanwe, mgbanwe ohere na mgbanwe reagent dị ka ihe mgbochi atọ nke mmeghari na ọrụ organoid. (Site na omenala organoid ruo n'ichepụta, 2026). Mgbanwe reagent bụ nke akwụkwọ nkọwapụta nwere ike ijikwa ozugbo.
Ihe kpatara na ụdịdị dị iche iche na-egbochi uru amụma
Esemokwu dị iche iche na-amachi uru amụma na-ezighi ezi, na nọmba isiokwu abụọ a na-ehotakarị na-atụ ihe dị iche iche. Achọpụtara nlebanya n'usoro nke ntụgharị asụsụ anụmanụ na mmadụ 71% mkpokọta toxicity concordance gafee ụdị, mana naanị 43% maka òké na 63% maka ndị na-abụghị òké (Ntụgharị asụsụ anụmanụ gaa na mmadụ: nyochaa nleba anya n'usoro, 2019). Otu ntụleghachi ahụ na-akọ na ọnụ ọgụgụ ndị na-adịghị mma dị obere maka nkịta, oke, oke, oke bekee na primates na-abụghị mmadụ, nke pụtara ihe na-adịghị mma na ụdị ndị ahụ nwere oke amụma amụma maka mmadụ, ebe nsonaazụ dị mma nwekwara ike ime na ụmụ mmadụ. Nnwale anụmanụ gosipụtara ike na-egosi nsi nke ga-eme, adịghị ekpochapụ ngwakọta.
Nke 5% Ọnụọgụ nkwado kacha mma megide asymmetry ahụ. Nyocha PLoS Biology chọpụtara usoro ọgwụgwọ ọrịa na-ekesa ọbara na 1% nkwado na nsogbu ahụike uche na 0%, megide 15% maka ọrịa musculoskeletal na 20% maka ọrịa kansa (Ineichen et al., PLoS Biology, 2024). Ndị ode akwụkwọ n'onwe ha na-achọpụta na nnabata nnabata ikpeazụ dị ala na-arụtụ aka n'ichepụta ntụpọ na ọmụmụ anụmanụ na nnwale ụlọ ọgwụ n'oge, na na oke ntụgharị asụsụ na-aga nke ọma nwere ike ịdị elu karịa ka ekwuputara n'ọtụtụ ebe. A 2026 nyochaa ka esi nweta ọnụ ọgụgụ ahụ akwụkwọ ndị a na-ehota ya nke ukwuu ma na-asọrịta mpi kama ịkwado ya n'onwe ya.
Ọnụego nnabata na-ejikọta ndu, ụlọ ọgwụ, mmetụta na-arụ ọrụ na azụmahịa. Ma pasentị nnabata nke anụmanụ na mmadụ dị ala ma ọ bụ pasentị toxicity-concordance egosighi onwe ya na nyocha mkpụrụ ndụ mmadụ chọrọ ka ọ dị elu.. Kwado ụdị ọhụrụ ahụ maka njedebe njedebe ya na ọnọdụ ojiji.
Kedu ihe na-eme ka peptide reagent dabara maka ihe nlereanya dabara na mmadụ
Otu peptide reagent dabara maka ihe nlere metụtara mmadụ mgbe akọwapụtara njiri mara ise ma gosipụta onwe ya.: njirimara, kemịkalụ ọcha na profaịlụ adịghị ọcha, ọdịnaya, counterion na nnu ụdị, na ike ma ọ bụ ihe omume dị mkpa na nyocha ahụ. Igwe njiri mara ise a bụ ngwa nkọwapụta nke akwụkwọ ntuziaka a na-ewulite na ya, ma ọ dị n'ihi na nyocha-naanị peptides anaghị anabata nnabata peptide akọwapụtara nke ọma na US ma ọ bụ EU.. "Oji nyocha naanị" anaghị edobe ịdị ọcha kacha nta, njirimara, ịmụ nwa, endotoxin ma ọ bụ ọkọlọtọ ike, ya mere onye ọrụ na-amanye nkọwapụta (Nyochaa Springer nke ụkpụrụ mmepe ọgwụ peptide, 2026). E gosipụtara isi iyi ahụ dị ka akwadoro akụkụ ụfọdụ na nyocha a, ya mere were usoro nhazi ahụ dị ka ihe ziri ezi ma kwado ya megide ụzọ ntinye akwụkwọ nke gị.
Àgwà ọma dị iche iche chọrọ ka egosipụtara arụmọrụ nyocha. Otu ikpo okwu nyocha nwere ike ịkwado ọtụtụ ebumnuche ma ọ bụrụ na akwadoro nke ọ bụla; nsonaazụ mpaghara kacha elu anaghị ewepụta njirimara ma ọ bụ ọdịnaya zuru oke. I Q2(R2) a nabatara na November 2023, na ụbọchị mmejuputa mpaghara kpebiri iche iche.
Ụdị ihe nlereanya ahụ na-agbakwụnye ihe mgbochi nke nkọwapụta ahụ ga-etinye. Organoid na akụkụ-na mgbawa na-arụ ọrụ ugboro ugboro na-adabere na matrices nke anụ ahụ sitere na anụmanụ.: Ntụleghachi nke Matrigel ọzọ sịntetik na-akọ na Matrigel sitere na sarcoma òké nwere ihe mejupụtara molekụla na-akọwapụtaghị ya yana njirimara akụrụngwa na-achịkwa nke ọma., na ihe ndị na-eto eto dị n'ọkwa dị iche iche n'ụfọdụ ogbe bụ nke achọpụtaghị n'ọgbe anọ nọọrọ onwe ha nwalere ma emechaa. (Ihe mgbakwunye sịntetịt maka Matrigel, 2020). Nkọwa peptide edere maka nyocha monolayer 2D anaghị ebufe ozugbo na usoro 3D nke nwere matriks., ya mere akụkụ ndị na-eso ya ji usoro ntụkwasị obi, ịdị ọcha, labeling na kwụsie ike dị ka ahịrị nkọwapụta dị iche karịa otu nọmba ịdị ọcha.
Kedu ka usoro ntụkwasị obi si ada na ihe ọdịda ọ bụla na-eme nyocha
Ikwesị ntụkwasị obi nke usoro na-ada n'ụzọ abụọ dị iche iche nke igwe, na ha nwere nsonaazụ dị iche iche maka nyocha. Usoro nhichapụ na-etolite n'oge nhazi usoro siri ike mgbe nchekwa Fmoc ezughị oke ma ọ bụ njikọ dara ada., ya mere yinye na-aga n'ihu na-enweghị otu ihe fọdụrụ; mkpịrịsị na-etolite mgbe a na-ekechi agbụ na-akwụsị itolite. Ụdị ihichapụ anaghị arụ ọrụ ma ọ bụ nke na-arụ ọrụ, nke na-agbaze ezigbo dose nọ n'ọrụ, ma ọ bụ ha nwere ike na-eme ihe dị ka ndị mmegide na-asọmpi (MOL na-agbanwe peptide microheterogeneity framework, 2026). Usoro ahụ bụ nke onye nrụpụta, ọ bụghị ọkọlọtọ ebipụtara, a na-akpọkwa ya ebe a maka usoro.
Mgbanwe oke mkpochapụ na-adabere na ihe fọdụrụ na-efu. Leu na Ile na-ekekọrịta ihe fọrọ nke nta ka ọ bụrụ monoisotopic 113.08406 Na. Lys na Gln adịghị: ihe fọduru ha dị ihe dịka 128.09496 na 128.05858 Na, n'otu n'otu, a 0.03638 Ya iche. Ma ngwa ọ na-edozi ọdịiche ahụ dabere na steeti ụgwọ, na-edozi ike na ịrụ ọrụ usoro. Lee ihe omumu ihe omumu nke mass-spectrometry.
|
ihichapụ |
Mass delta |
ndetu nchọpụta |
|---|---|---|
|
Gly |
-57.02 |
Obere mkpochapụ pola na-ejikọta ọnụ; LC-MS chọrọ |
|
Ala |
-71.04 nke |
Na-edozi n'ọtụtụ n'azụ gradients |
|
S Peptide S N'ogbe bụ |
-87.03 nke |
Ihe egwu jikọrọ ọnụ na ọnụ ọgụgụ kacha elu |
|
Val |
-99.07 nke |
Enwere ike ịchọpụta Peptides nke LC-MS |
|
Leu / Ya na |
-113.08 Da |
Isobaric ụzọ; enweghị ike ịmata ọdịiche dị na oke naanị |
|
Lys / Gln |
Lys: -128.09496 Da; Gln: -128.05858 Da |
Nso-isobaric, ọ bụghị otu kpọmkwem oke; mkpebi dabere na usoro |
Epimers bụ ikpe siri ike. Racemisation na D-amino-acid epimers na-eme n'oge amino acid na-arụ ọrụ na njikọta na nke a na-ahụkarị na cysteine na histidine.; epimers na-ekekọrịta oke molekụla nke ọma yana ọ fọrọ nke nta ka ọ bụrụ njide, nke na-eme ka ha bụrụ otu n'ime adịghị ọcha siri ike ikewapụ (CertikLabs, 2026). A 2026 analytical-chemistry atụmatụ na nyocha peptide na-eme ka isi ihe dị n'ozuzu ya: usoro iche iche, deamidation, oxidation, Acylation variants na epimers nwere ike jikọta ọnụ, dozie akụkụ ụfọdụ ma ọ bụ nọdụ ala n'okpuru ọnụ ọgụgụ isi, na nyocha nke mbụ nwere ike ịgụta ha ọnụ na-akọwapụtaghị ha (The Analytical Scientist, 2026).
Ebe ihe akaebe na-akwụsị: Ọ nweghị ebe dị na nlebanya a na-akọwapụta ngbanwe ike nke otu adịghị ọcha mkpọkpọkpọtụrụ ma ọ bụ nke epimeric kpatara.. A na-akwado usoro na mbinye aka dị ukwuu; ọnụ ọgụgụ "epimers na-ebelata ike site na X%" abụghị, na ekwesịghị ịpụta na nkọwapụta.
Ihe kpatara na pasentị ịdị ọcha enweghị ike ịkọwa Peptide
Otu pasent nke ịdị ọcha enweghị ike ịkọwa peptide n'ihi na ịdị ọcha HPLC bụ oke mpaghara, ọ bụghị akụkụ nke uka. Ịdị ọcha HPLC bụ oke nke mpaghara ebumnuche-elu na mpaghara ọnụ ọnụ niile achọpụtara, na peptide nwere ike ịre na 97% HPLC dị ọcha ebe ọdịnaya peptide net dị ala. Mmebi nke ndị na-ebubata ihe na-arụ ọrụ nke mejupụtara ihe atụ peptide na-enye mgbakọ na mwepụ: 10 mg a napụtara na 97% HPLC ịdị ọcha na 40% Ọdịnaya peptide site na nyocha amino-acid na-amịpụta 3.88 mg nke peptide lekwasịrị anya n'ezie (faịlụ teknụzụ GenScript, emechiri emechi, ewepụtara 2026). Nke ahụ bụ a 61% mkpirisi n'etiti nọmba dị na asambodo na nọmba dị na tube.
Ibu Counterion na-akpata nnukwu akụkụ nke oghere ahụ. Otu teknuzu faịlụ na-akọ na-emegide ọdịnaya, A na-ahụkarị trifluoroacetate, na-agbakarị ọsọ 10% ka 30% nke peptide uka a napụtara dabere na mkpokọta ihe fọdụrụ, na ihe atụ ọrụ nke a 1,500 Da peptide na-ebu TFA anọ na 23.3% TFA site na oke (GenScript, emechiri emechi). Mmiri na ihe mgbaze fọdụrụ na-ewere akụkụ nke fọdụrụnụ. Ọ dịghị nke ọ bụla n'ime ihe ndị a bụ adịghị ọcha n'echiche sịntetik; ha bụ uka nke na-abụghị peptide.
Nduzi ịdị ọcha nke ndị na-ebubata ya site na maapụ ngwa opekempe ịdị ọcha HPLC ka ekwesịrị iji: n'elu 75% maka ELISA na peptide arrays, n'elu 85% maka in-vitro bioassays na maapụ epitope, n'elu 95% maka quantitative receptor-ligand interactions na quantitative proteolysis, na n'elu 98% maka crystallography, SAR na ihe ụlọ ọgwụ (GenScript tụrụ aro ntuziaka ịdị ọcha, emechiri emechi). Nke a bụ maapụ ngwa ndị ere ere, Ọ bụghị ICH ma ọ bụ USP chọrọ, ma ekwesịrị ịgụ ya n'akụkụ mgbakọ na mwepụ ọdịnaya kama ịgụ ya. Nnwale ọnụọgụ nnabata nke ligand akọwapụtara na 95% HPLC dị ọcha mana ewepụtara na 40% ọdịnaya na-agba ọsọ na roughly 38% n'ụkpụrụ molar a chọrọ ma ọ bụrụ na ejiri ọnụ ọgụgụ ọdịnaya iji dozie nha.
Nsonaazụ nkọwapụta bụ ihe achọrọ ahịrị abụọ: kọọ ịdị ọcha HPLC ma kọọ ọdịnaya site na nyocha amino-acid ma ọ bụ mkpebi nitrogen, wee kwupụta nke ọnụ ọgụgụ nke protocol nyocha na-eji maka molarity. A 2026 njirimara nyocha na-eme otu arụmụka ahụ site na ntụziaka ọzọ, N'ịkọwa na otu uru ịdị ọcha RP-HPLC gbakwunyere oke adịghị ezughi oke n'ihi na ụdị microheterogeneous nwere ike ịbụ isobaric ma ọ bụ nwee njikọ chiri anya. (The Analytical Scientist, 2026).
Kedu ka Nhọrọ ịde aha si gbanwee agụpụta na 3D na Microfluidic Formats
Nhọrọ ịde aha na-agbanwe agụgharị n'ụdị 3D na microfluidic n'ihi na akara ahụ na-agbanwe njirimara physicochemical nke na-achịkwa ma njide nyocha yana mmekọrịta ngwaọrụ.. Akara fluorescent bụ ngwaọrụ ọkọlọtọ maka onyonyo, cytometry eruba, nyocha njide na nsochi cellular, na a 2024 ntụnyere protocol maka nkwụsi ike peptide chọpụtara na atụmatụ ịde aha n'onwe ya na-emetụta mbelata atụlere: Ọmụmụ ihe ahụ tụlere ọrụ nke akara fluorescent na nkwụsi ike peptide wee jiri nsonaazụ megide peptides akpọrọ isotopically., na-akọwapụta uru nke onye ọ bụla nke ụzọ abụọ ahụ (Kohler et al., ntụle nke protocol iji nwalee nkwụsi ike peptide n'ime ọbara, 2024). Ọ bụrụ na akara na-agbanwe nha, ogo nke labeling bụ oke nkọwapụta, ọ bụghị ihe odide ala ala peeji katalọgụ.
<klas ọgụgụ ="blọọgụ-akara ngosi" ụdị ="oke-obosara:640px;oke:1.5rem akpaaka;font-nha:12px;ahịrị-ịdị elu:1.3;agba:eketa"> <svg viewBox="0 0 560 380" ụdị ="oke-obosara: 100%; elu: akpaaka; font-ezinụlọ: 'Inter', usoro-ui, sans-serif; agba: #1e293b; --chaatị-mechiri emechi: #64748b;" ọrụ ="img" aria-labeledby="24-h-recovery-pdms-vs-coc-title 24-h-nnaghachi-pdms-vs-coc-desc"> <ịke> /* Onye nrụpụta na-etinye eserese ahụ n'ime iframe nke ihe ndabere ya dị oji, na iframe bụ ọdịdị dị iche na chaatị ahụ, ya mere eriri igbe akwụkwọ ozi gosipụtara dị ka okpokolo agba gbara ya gburugburu (prod 09-22). Akwụkwọ dị n'ime iframe pụtara ìhè na ndabara; esere ya ebe a na-ekpuchi ndabere elementrị, na mgbe e debere chaatị ahụ kama nke a dabara na ihe ọ bụla. Debe brackets n'akuku na ngọngọ a: A na-atụgharị akụkụ ụdị n'ime SVG dị ka ọdịnaya nke mba ọzọ, ya mere otu nkwado kpafuru akpafu na-atụfu iwu niile dị na ya. */ html, ahu { ndabere: #fffff; oke: 0; } @mgbasa ozi (na-ahọrọ-ebelata-mmegharị: belata) { * { animation: onweghi !mkpa; mgbanwe: onweghi !mkpa; } } </ịke> <ziri ezi x="0" y="0" obosara ="560" elu ="380" rx="8" juru ="#fffff" /> <aha id="24-h-nnaghachi-pdms-vs-coc-aha">24 h mgbake: PDMS vs COC</aha> <desc id ="24-h-nweghachi-pdms-vs-coc-desc">h mgbake: PDMS vs COC, dị ka e si kpaa nkata site n'isi iyi e zoro aka na ya. 24 h mgbake: PDMS vs COC. data mmanya agbakọtara: Primidone: PDMS 83.8, COC 86.8; Amlodipine: PDMS 2.8, COC 18.1; Loperamide: PDMS 5.3, COC 50.8. Isi mmalite: Ngwa ACS etinyere & Ọnụ ụzọ 2021-09-16.</desc> <ederede x ="280.0" y="29" ederede-arịlịka ="etiti" font-size ="18" font-arọ="800" juru ="Agba ugbu a">24 h mgbake: PDMS vs COC</ederede> <ahịrị x1="72" y1="277.0" x2="492" y2="277.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="230.8" x2="492" y2="230.8" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="184.5" x2="492" y2="184.5" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="138.2" x2="492" y2="138.2" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="92.0" x2="492" y2="92.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ederede x ="66" y="281.0" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">0</ederede> <ederede x ="66" y="234.8" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">25</ederede> <ederede x ="66" y="188.5" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">50</ederede> <ederede x ="66" y="142.2" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">75</ederede> <ederede x ="66" y="96.0" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">100</ederede> <ziri ezi x="72.0" y="62" obosara ="10" elu ="10" juru ="#f97316" /> <ederede x ="87.0" y="71" font-size ="11" juru ="Agba ugbu a">PDMS</ederede> <ziri ezi x="133.8" y="62" obosara ="10" elu ="10" juru ="#38bdf8" /> <ederede x ="148.8" y="71" font-size ="11" juru ="Agba ugbu a">COC</ederede> <ziri ezi x="124.0" y="122.0" obosara ="16.0" elu ="155.0" juru ="#f97316" /> <ederede x ="132.0" y="118.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">83.8</ederede> <ziri ezi x="142.0" y="116.4" obosara ="16.0" elu ="160.6" juru ="#38bdf8" /> <ederede x ="150.0" y="112.4" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">86.8</ederede> <ederede x ="142.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="142.0" dy="0">Primidone</tsp></ederede> <ziri ezi x="264.0" y="271.8" obosara ="16.0" elu ="5.2" juru ="#f97316" /> <ederede x ="272.0" y="267.8" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">2.8</ederede> <ziri ezi x="282.0" y="243.5" obosara ="16.0" elu ="33.5" juru ="#38bdf8" /> <ederede x ="290.0" y="239.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">18.1</ederede> <ederede x ="282.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="282.0" dy="0">Amlodipine</tsp></ederede> <ziri ezi x="404.0" y="267.2" obosara ="16.0" elu ="9.8" juru ="#f97316" /> <ederede x ="412.0" y="263.2" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">5.3</ederede> <ziri ezi x="422.0" y="183.0" obosara ="16.0" elu ="94.0" juru ="#38bdf8" /> <ederede x ="430.0" y="179.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">50.8</ederede> <ederede x ="422.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="422.0" dy="0">Loperamide</tsp></ederede> <ederede x ="280.0" y="366" ederede-arịlịka ="etiti" font-size ="10" juru ="anyi(--chaatị-mechiri emechi, Agba ugbu a)">Isi mmalite: Ngwa ACS etinyere & Ọnụ ụzọ (2021-09-16)</ederede> </svg> </ọgụgụ>
Ngwa ngwaọrụ bụ mgbanwe nke abụọ. A 2021 Ngwa ACS etinyere & Ọmụmụ sorption interface tụrụ mgbake mgbe emechara 24 awa nke static incubation na 37 °C sitere na a 100 µM ịmalite itinye uche wee hụ ndịiche dabere na ihe dị nkọ: amlodipine gbakere na 2.8% sitere na PDMS megide 18.1% site na cyclic olefin copolymer, loperamide na 5.3% megidere 50.8%, na primidone na 83.8% megidere 86.8%, na caffeine na-egosi enweghị nnukwu ọdịiche (Usoro nke Neuropsychopharmaca na Ngwa Microfluidic, 2021). Ngwakọta ndị a nwalere bụ obere ụmụ irighiri ihe na esiji, ọ bụghị peptides, ya mere nyefe bụ mechanistic: ịdị ukwuu na-adabere na lipophilicity peptide n'onwe ya yana n'ogo elu-na-olu nke ngwaọrụ ahụ..
Nyocha ụlọ nyocha dị na mgbawa nke mfu ọgwụ na ihe mgbawa na-enye ihe nlegharị anya nhazi. Ọnwụ PDMS nwere ike karịa 50% maka ogige hydrophobic: Cy3 NHS ester na logPe 7.2 furu efu karịa 50%, rhodamine B tụfuru karịa 50% na logPe 5.7 na karịa 25% na logPe 6.7, ebe paclitaxel furu efu karịa 5%, na tubing nyere ihe na-erughị 7% nke ngụkọta ọnwụ (Ụlọ nyocha na mgbawa, 2017). Otu ọmụmụ na-egosi na ịba ụba nke Péclet, site n'ịkwalite ọsọ ọsọ ma ọ bụ ibelata akụkụ ọwa, nwere ike ijide ọnwụ n'okpuru 5% ọbụna na elu nkebi ọnụọgụgụ. Nsonaazụ nkọwapụta bụ ụzọ jikọtara ọnụ: kwupụta ogo nke akara na nkewa na mgbake atụnyere ihe arụrụ arụ, ma tozuo ihe ngwaọrụ na usoro ịgbasa megide onye nnọchi anya peptide tupu itinye ya na dose.
Otu esi atụle nkwụsi ike Peptide na Matriks Model n'ezie
A ghaghị tụọ nkwụsi ike Peptide na matriks ihe nlereanya n'ezie n'ihi na ọnụego nbibi dabere na matriks, na mgbasa ahụ buru ibu iji gbanwee nkwubi okwu ọmụmụ. A 2024 ntụnyere protocol tụrụ peptide ọkara ndụ n'ime ọbara mmadụ gbazere 1:1 ya na DPBS na 10 µM na 37 Celsius C: otu analọgụ ghrelin fọdụrụnụ 36 nyere 50.5 h (95% CI 39.8–66.7 elekere), ebe analọgụ yiri ya gosiri na ọ nweghị mmebi n'otu windo elekere 72 ahụ (Kohler et al., 2024). Peptides asaa nke 9 ka 36 a nwalere foduru. Otu nnyocha ahụ chọpụtara na peptide yiri ya nyere ọkara ndụ dị iche ruo okpukpu abụọ n'etiti batches plasma sitere na ndị na-enye onyinye dị iche iche., na nkwụsi ike na HEK-293 supernatant dị elu karịa na plasma maka atọ n'ime peptides anọ, na otu peptide na-akpụ akpụ 3.2 h na plasma 23.3 h na HEK-293 supernatant. Hgh ma ọ bụ Peptides
Ezipụta nkwadebe nlele ma nyochaa mgbake mmịpụta, mmetụta matrix na ọnwụ dabere na oge. Mgbake na-ezughị ezu anaghị eme ka nyocha nkwụsi ike ghara ịdị irè ma ọ bụrụ na ejiri ya mara ya, zuru oke na-agbanwe agbanwe ma jiri njikwa dabara adaba. Enwere ike chegharịa mgbake agbanweghị dị ka mmebi.
Maka ụdị 3D na matriks agbakwunyere, ntọala ihe akaebe dị gịrịgịrị ma ekwesịrị ka ewere ya dị ka nke a. Enweghị ọmụmụ ihe na nyocha a na-akọ akụkọ mmebi nke peptide ọkara ndụ na usoro omenala organoid ma ọ bụ na matrix 3D nwere serum nwere ọnọdụ yiri ya na ọrụ plasma.. Ya mere nkọwapụta nke enweghị ike bụ usoro chọrọ karịa ọnụọgụ: kọwaa matriks, okpomọkụ, ntinye uche mmalite, windo nlele na usoro nchọpụta, wee tụọ ọkara ndụ dị na matriks ahụ tupu ọmụmụ ihe amalite. I Q5C, ntuziaka nkwụsi ike maka ngwaahịa ndu, dị mkpa ebe a maka nhazi ya karịa oke ya: ọ na-ekwu na ngwaahịa ndị ihe na-arụ ọrụ ya bụ protein ma ọ bụ polypeptides "na-enwe mmetụta karịsịa maka ihe gburugburu ebe obibi dị ka mgbanwe okpomọkụ., oxidation, ìhè, ionic ọdịnaya, na ịkwa osisi," na na ịnọgide na-enwe conformation na ọrụ na-adabere na-abụghị covalent nakwa dị ka covalent agha (I Q5C, 1996, ọdịnaya ugbu a 2018). Q5C abụghị peptide-reagent-kpọmkwem, na e kwesịghị ịkpọ ya ka a ga-asị na ọ bụ ya.
Ijikwa nchekwa na-enye otu ahịrị nkọwapụta. Ntuziaka nchekwa ndị na-ebubata ngwaahịa na-ekwu na peptide arụgharịrị na mmiri bacteriostatic na 2-8 Celsius C na-ejigide iguzosi ike n'ezi ihe. 28 ka 90 ụbọchị, na peptide na mmiri na-adịghị ọcha na-enweghị ihe nchekwa kwesịrị iji n'ime 24 awa, mmeghachi omume ahụ ruru ihe dị ka okpukpu abụọ maka nke ọ bụla 10 Celsius C na-ebili, na aliquoting a na-eji otu eme ihe bụ mbelata ọkọlọtọ maka nchịkọta friza-thaw (Peptra Labs nchekwa protocol, 2026). Nke a bụ nduzi onye na-ere ahịa, ọ bụghị ọmụmụ nkwụsi ike tụrụ atụ, na ekwesịrị ịnwapụta ya megide data matriks nke gị kama ịnakwere dị ka ntọhapụ ntọhapụ.
Ihe onye nyocha chọrọ na ngwugwu data Peptide
Onye nleba anya chọrọ ngwugwu data nke enwere ike isi wughachi ọmụmụ ihe, ọ bụghị akwụkwọ nyocha naanị. Ntuzi aka iguzosi ike n'ezi ihe nke data MHRA na-akọwa ọkọlọtọ: ALCOA (Ekepụtara, Enwere ike ịkọwa, Nke dịkọrọ ndụ, Nke mbụ, ziri ezi) gbakwunyere zuru ezu, Na-agbanwe agbanwe, Na-adịgide adịgide ma dị, na-enweghị ọdịiche na atụmanya nke ọ bụla acronym eji, na ọ na-ekwu na raw data ga-ekwe ka nwughari n'uju nke ihe omume na metadata bụ akụkụ dị mkpa nke ndekọ mbụ. (MHRA GXP Data iguzosi ike n'ezi ihe na nkọwapụta, Ndozigharị 1, Maachị 2018). Nke a bụ usoro GXP izugbe, ọbụghị nke akọwapụtara NAM, Enwere ike ịkọwa ya naanị dịka ọkọlọtọ dataset ọ bụla ga-ezute.
Tinyere na peptide reagent, ọkọlọtọ ahụ na-emepụta ndepụta ubi. Njirimara chọrọ oke gbakwunyere nkwenye ọkwa usoro, LC-MS/MS ma ọ bụ maapụ peptide, n'ihi na oke oke naanị enweghị ike ịmata ọdịiche nke mkpochapụ isobaric ma ọ bụ epimers (The Analytical Scientist, 2026). Ịdị ọcha kemịkalụ chọrọ chromatogram, ọ bụghị naanị pasentị, ya mere onye nleba anya nwere ike ịhụ ebe ọnụ ọgụgụ dị elu na-anọdụ ala n'akụkụ ọnụ ọgụgụ isi. Ọdịnaya chọrọ nyocha amino-acid ma ọ bụ mkpebi nitrogen na usoro akpọrọ. Ụdị mgbochi na nnu chọrọ uru ekwuputara, Nyere 10% ka 30% oke oke maka TFA (GenScript, emechiri emechi). Ike chọrọ nyocha dabara na ngụpụta echere.
|
ubi ngwugwu |
Ihe ọ ga-enwerịrị |
Ihe mere onye nleba anya chọrọ ya |
|---|---|---|
|
njirimara |
Mass na-adịghị mma gbakwunyere LC-MS/MS ma ọ bụ maapụ peptide |
Uka na-adịghị mma na-atụfu nhichapụ nke isobaric na epimers Onye nrụpụta Polypeptide |
|
Ịdị ọcha |
Chromatogram nwere njikọ kacha elu, usoro na gradient |
Mpaghara-% enweghị akara ahụ enweghị ike ịlele ya |
|
Ọdịnaya |
Nyocha amino acid ma ọ bụ mkpebi nitrogen, usoro aha ya |
Na-atụgharị mpaghara-% ka ọ bụrụ ọnụọgụ molar nwere ike ịdị arọ |
|
Mkpesa / ụdị nnu |
Mkpesa ekwupụtala na pasentị nke oke ewepụtara |
TFA na-abụkarị 10-30% nke oke |
|
Ike |
Nnwale dabara na ngụpụta echere |
Na-akwado na ihe ahụ na-arụ ọrụ, ọ bụghị naanị ugbu a |
|
Nkwụsi ike |
Matrix, okpomọkụ, itinye uche, window nlele, usoro |
Ọnụego dabere na Matrix; enweghị ndabara ọkara ndụ dị |
|
Ndekọ |
Faịlụ data efu, metadata, ụzọ nyocha, ezi mbipụta |
ALCOA+ nwughari chọrọ |
Ihe abụọ nhọrọ dị na listi ahụ mgbe usoro ihe nlereanya chọrọ ha. Edebere ule Endotoxin na akwụkwọ ọmụmụ ọmụmụ site na naanị nyocha-eji ọnọdụ, na omenala 3D nwere ihe mgbochi mebiri emebi na-enwe mmetụta maka mmetọ karịa olulu mmiri 2D.. Ekwesịrị ịrịọ ha abụọ n'ụzọ doro anya kama iche. Otu echiche ahụ na-emetụta ntozu nza: n'ihi na ọdịnaya na mgbagha dịgasị iche site n'ife nza, nkọwapụta nke na-eme otu nza megide ọkọlọtọ akwụkwọ wee nabata nza na-esote na asambodo naanị abụghị nkọwapụta., ọ bụ otu nha.
Ebe nkọwapụta ahụ zutere oche
Tupu ịtụ, kọwaa mmetụta adịghị ọcha nke assay, njirimara nke otutu na usoro ọdịnaya. Gbakọọ ntinye uche site na ndabere ọdịnaya akọpụtara wee zere mmezi ugboro abụọ ma ọ bụrụ na ọ tụrụlarị peptide lekwasịrị anya. Tozuo mgbake na nkwụsi ike ngwaọrụ site na iji ezigbo nrụpụta na matriks; Nsonaazụ sorption obere-molecule abụghị nkọwa mgbake peptide.
Usoro ahụ nwere oke kwesịrị ịkọwa. Ọ naghị anọchi anya nkwado ndabere-okwu, na enweghị isi na nyocha a aha njirimara NAM gosipụtara na-adịghị ala na nnwale anụmanụ maka otu ọnọdụ ojiji.. Ọ naghị edozi ajụjụ ike epimer, n'ihi na ọnweghị ọnụ ọgụgụ mgbanwe ike maka otu adịghị ọcha epimeric akọwapụtara. Ọ naghị enye akara ngbanwe matriks dị nza-to-lot ma ọ bụ pasent mgbasa ozi peptide kpọmkwem., Ha abụọ ka edoghị ọnụ na isi mmalite ndị a nyochara. Ma ọ dịghị eleba anya n'ajụjụ nchịkwa nke ma a ga-anabata dataset NAM nyere, n'ihi na ọ nweghị akwụkwọ na-akọ ole ntinye akwụkwọ IND dabeere na NAM anabatara ma ọ bụ ole ejidere ụlọ ọgwụ enyela na data NAM..
Ihe ọ na-enye bụ nkọwapụta nwere ike dee, kwadoro ma wughachi ya. Àgwà ise ahụ (njirimara, profaịlụ dị ọcha na adịghị ọcha, ọdịnaya, counterion na nnu ụdị, ike) Maapụ ọ bụla gaa na usoro nyocha aha ya n'okpuru ICH Q2(R2) (I Q2(R2), 2023), na nke ọ bụla na-emepụta ndekọ na-eju ụkpụrụ nrụpụta MHRA (MHRA, 2018). Nzọụkwụ ọzọ bụ iburu tebụl ubi dị n'elu gaa na ndị na-ebubata gị ugbu a ma jụọ nke ubi dịlarị, nke chọrọ usoro mgbanwe, na nke gị onwe gị QC pipeline ga-emepụta. Ntụle nkọwapụta megide otu usoro bụ ụzọ kachasị ọsọ iji chọpụta ebe oghere dị.
Ajụjụ a na-ajụkarị
Nwere ike a 98% HPLC-peptide dị ọcha ka na-ada nyocha?
Ee, na ọdịda na-emekarị enweghị ihe jikọrọ ya na isi elu. Ịdị ọcha site na HPLC bụ oke mpaghara tụrụ na otu wavele ogologo; ọ dịghị ihe ọ na-ekwu banyere ihe ọzọ dị na vial. Ngwaahịa ihichapụ na-ejikọta ya na ebumnuche, residual counterion, na agbụ mmiri niile na-aga na ihe onwunwe na ihe niile na-atụ n'ime dose. Mgbe a na-ewere peptide dị oke arọ na-enweghị mgbazi ọdịnaya, Nnwale ahụ na-anata obere ihe ezubere iche karịa ka protocol chere, na ike ma ọ bụ njide usoro nwere ike ịgbanwe maka nke ahụ naanị. A na-arụ ọrụ dị iche iche nke ịdị ọcha-na-ọdịnaya na ngalaba ịdị ọcha dị n'elu.
Ọ dị ọcha HPLC yana ọdịnaya peptide net bụ otu nha?
Mba. Ha na-aza ajụjụ dị iche iche. HPLC dị ọcha na-akọwa oke nke ihe na-anabata UV n'ime oke ebumnuche metụtara ihe ọ bụla ọzọ na chromatogram.. Ọdịnaya peptide net na-akọwa ole n'ime uka ewepụtara bụ n'ezie peptide, mgbe counterion na mmiri na-wepụ. Nlereanya nwere ike ịdị mma na nha nke mbụ ma gbadaa nke ukwuu na nke abụọ, nke mere na ọnụọgụ abụọ ahụ ji n'akụkụ ọnụ na nkọwapụta karịa otu na-eguzo maka nke ọzọ.
Kedu ka m ga-esi gwa mkpọtu site na epimer?
Malite na uka. Mkpọtu na-ewepụ ihe fọdụrụ, ya mere uka na-agbanwe site na ofu, ego a ga-ebu amụma maka amino acid ọ bụla na-efu, na LC-MS ga-egosi ya dị ka ụdị dị iche ma ọ bụrụ na ọ na-ejikọta ọnụ. Epimer nwere otu uka ka ebumnuche, n'ihi na usoro adịghị emebi emebi na naanị stereochemistry n'otu etiti agbanweela. Ya mere Mass spectrometry enweghị ike idozi ya. A na-achọpụta epimers site na nkewa chromatographic megide ọkọlọtọ ntụaka ma ọ bụ site na ụzọ chiral dị ka ntụgharị anya.. Akụkụ usoro-ikwesị ntụkwasị obi dị n'elu na-ekpuchi ọnọdụ ọdịda ọ bụla yana nsonaazụ nyocha ya.
Nkwụsi ike na nchekwa ọ na-ebu amụma nkwụsi ike na usoro organoid?
Mba. Nkwụsi ike nke nchekwa bụ ntọala bara uru, ma ọ naghị ebufe na matriks dị mgbagwoju anya. Usoro mgbasa ozi Organoid na akụkụ-na-chip nwere protease, akụkụ serum na ọrụ sitere na cell nke ihe nchekwa enweghị, na otu peptide nwere ike iweda n'ụdị dị iche iche gafee matrices. Tụọ nkwụsi ike na matriks nke nyocha ahụ ga-eji n'ezie, ma kọọ matrix, okpomọkụ, usoro itinye uche na nchọpụta n'akụkụ ọkara ndụ ka enwere ike ịkọwa ọnụọgụgụ ahụ.
Kedu ihe ga-enwerịrị akwụkwọ nyocha iji bụrụ nke a ga-azara ọnụ?
Opekempe: HPLC nyocha na chromatogram, Mass spectrometry na-akwado njirimara, na nyocha nke amino acid maka oke. Ndị atọ ahụ na-ekpuchi ịdị ọcha, njirimara na ọdịnaya, nke bụ nkwupụta atọ onye nyocha ga-anwale. Nyocha ihu, ọdịnaya mmiri nke Karl Fischer, Nnwale endotoxin na ntụgharị anya bụ mgbakwunye nhọrọ nke ga-adị mkpa mgbe nyocha ahụ nwere mmetụta maka ụdị nnu, osmolarity, endotoxin ma ọ bụ stereochemistry. Akụkụ data-ngwugwu dị n'elu na-edepụta mpaghara ndị nyocha na-atụ anya ịhụ.
A na-ahazi naanị peptides-eji nyocha?
Ọ bụghị site na peptide-kpọmkwem premarket chọrọ. Nhazi RUO na-etinye ọrụ maka ahụike n'aka onye zụrụ ya, nke pụtara na nkọwapụta bụ nke gị ide na ịgbachitere. Nke ahụ bụ nsonaazụ bara uru nke ntuziaka dum: ọkwa ịdị ọcha, ụdị counterion, labeling kemịkalụ, Ndozi ọdịnaya na nnwale nkwụsi ike bụ nhọrọ ị na-eme na akwụkwọ, Ọ bụghị ndabara onye na-ebubata nwere iwu ịnye.
Ndị ụzọ ọhụrụ dị njikere iji dochie ule anụmanụ?
Ọbụbeghị, na kpachara anya hazie usoro iheomume. Ụzọ ụzọ FDA na-esetịpụ a 3 ka 5 ihe mgbaru ọsọ afọ nke ime ka ọmụmụ anụmanụ dị iche karịa ụkpụrụ maka nchekwa nchekwa na nyocha nsí, ya na NAM kwadoro na-ebu ibu karịa ka ha na-etolite (Ụzọ FDA iji belata Nnwale anụmanụ na ọmụmụ nchekwa nchekwa nke preclinical, Eprel 2025). Tebụl CDER bipụtara na Ọktọba 2025 depụtara ọnọdụ ebe enwere ike ịnabata mmemme na-abụghị nke ụlọ ọgwụ gụnyere NAM. Nkatọ ndị ebipụtara nke map okporo ụzọ na-ajụ ma nkwado na akụrụngwa ntozu nwere ike ịga n'ihu na nhazi oge ahụ. Ihe akaebe na-enyeghị bụ ọnụọgụ nkuchi ma ọ bụ data ejidere ụlọ ọgwụ, ya mere ọnọdụ n'eziokwu bụ na a na-edozi ntụziaka na usoro ahụ adịghị akwado. Akụkụ ihe nlere anya dị n'elu na-ekpuchi ihe ihe nlereanya dabara na mmadụ ga-egosipụta tupu ọ buru ibu ahụ.
Mmechi
Ngbanwe usoro iwu na ụdị ndị metụtara mmadụ bụ eziokwu, mana reproducibility nke ụdị ndị ahụ dabere na njirimara reagent nke akwụkwọ nyocha anaghị ekpuchi. Nkọwapụta àgwà ise ahụ (njirimara, kemịkalụ ọcha na profaịlụ adịghị ọcha, ọdịnaya, counterion na nnu ụdị, ike) na-enye njirimara nke ọ bụla n'ime usoro nkwado nke ya n'okpuru ICH Q2(R2), na tebụl ngwungwu data na-enye usoro ọ bụla ndekọ onye nyocha nwere ike wughachi ya n'okpuru ọkọlọtọ MHRA ALCOA+. Ụdị ọdịda atọ nke akọwapụtaghị megide ya bụ ihe akaebe na-akọwapụta: nọmba dị ọcha nke na-abụghị ọnụọgụ ọdịnaya, nhichapụ ma ọ bụ epimer nke na-anọdụ ala n'okpuru isi elu, na matriks ma ọ bụ ngwaọrụ na-ewepụ peptide tupu mkpụrụ ndụ ahụ ahụ ya.
Iwu mkpebi dị mkpụmkpụ. Hazie ihe agụpụtara, tọọ mmezi ọdịnaya, tozuo usoro, ma tụọ nkwụsi ike na matriks n'ezie. Ebe ihe akaebe na-akwụsị, kwuo ya: Ọ nweghị NAM kwadoro ka egosipụtara na ọ bụghị nke dị ala na nnwale anụmanụ maka ọnọdụ ejiri aha akpọrọ, Ọ dịghị pasent mgbasa ozi peptide akọwapụtara maka PDMS ma ọ bụ COC, na ọnweghị ọkara ndụ a tụrụ atụ maka peptide na usoro organoid dị na nyocha a. Ọdịiche ndị ahụ bụ ihe kpatara onye ọrụ ga-eji dee nkọwapụta ahụ kama ketara n'aka onye na-ebubata ya. Were okpokoro ubi gaa n'usoro ọzọ gị wee jụọ mpaghara ndị dịlarị, nke chọrọ usoro mgbanwe, na nke gị onwe gị QC pipeline ga-emepụta.
Nkpughe: Onye edemede ahụ nwere mmasị azụmahịa na njikọ peptide na ọrụ nyocha. Ntuziaka a bụ usoro nkọwapụta maka nlebanya reagent na ọbụghị ụkpụrụ akwadoro ma ọ bụ akwụkwọ ntinye iwu na-achịkwa..
